摘要：The potential of the systemic antifungal treatment of non-immunocompromised patients with sepsis,extra-digestive Candida colonization and multiple organ failure is unknown, although it representsthree out of four antifungal treatments prescribed in intensive care units. It may allow an earlytreatment of invasive fungal infection at incubation phase, but exposes patients to unnecessaryantifungal treatments with subsequent costs and antifungal selection pressure. As early diagnostictests for invasive candidiasis are still considered insufficient, the potential of this strategy needs to bedemonstrated by a randomized controlled trial. Such a trial is currently ongoing.
Loading...
